Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA.
Bae M, Kim G, Lee TR, Ahn JM, Park H, Park SR, Song KB, Jun E, Oh D, Lee JW, Park YS, Song KW, Byeon JS, Kim BH, Sohn JH, Kim MH, Kim GM, Chie EK, Kang HC, Kong SY, Woo SM, Lee JE, Ryu JM, Lee J, Kim D, Ki CS, Cho EH, Choi JK. Bae M, et al. Among authors: kim g, kim d, kim bh, kim gm, kim mh. Nat Commun. 2023 Apr 10;14(1):2017. doi: 10.1038/s41467-023-37768-3. Nat Commun. 2023. PMID: 37037826 Free PMC article.
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG). Park YH, et al. Among authors: kim sb, kim jy, kim ty, kim sh, kim gm, kim jh. Eur J Cancer. 2017 Nov;86:385-393. doi: 10.1016/j.ejca.2017.10.002. Epub 2017 Nov 5. Eur J Cancer. 2017. PMID: 29100193 Clinical Trial.
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
Park YH, Lee KH, Sohn JH, Lee KS, Jung KH, Kim JH, Lee KH, Ahn JS, Kim TY, Kim GM, Park IH, Kim SB, Kim SH, Han HS, Im YH, Ahn JH, Kim JY, Kang J, Im SA. Park YH, et al. Among authors: kim sb, kim jy, kim ty, kim sh, kim gm, kim jh. Int J Cancer. 2018 Dec 15;143(12):3240-3247. doi: 10.1002/ijc.31651. Epub 2018 Nov 7. Int J Cancer. 2018. PMID: 29978467 Free article. Clinical Trial.
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Lee JB, Jung M, Beom SH, Kim GM, Kim HR, Choi HJ, Sohn JH, Ahn JB, Rha SY, Chung HC. Lee JB, et al. Among authors: kim gm, kim hr. Invest New Drugs. 2021 Oct;39(5):1366-1374. doi: 10.1007/s10637-021-01085-7. Epub 2021 Mar 15. Invest New Drugs. 2021. PMID: 33723724 Free PMC article. Clinical Trial.
Genomic landscape of extraordinary responses in metastatic breast cancer.
Lim SM, Kim E, Jung KH, Kim S, Koo JS, Kim SI, Park S, Park HS, Park BW, Cho YU, Kim JY, Paik S, Kwon NJ, Kim GM, Kim JH, Kim MH, Jeon MK, Kim S, Sohn J. Lim SM, et al. Among authors: kim jy, kim e, kim s, kim si, kim gm, kim mh, kim jh. Commun Biol. 2021 Apr 9;4(1):449. doi: 10.1038/s42003-021-01973-x. Commun Biol. 2021. PMID: 33837242 Free PMC article.
604 results